Amgen, Biogen, Genentech, Genzyme, Life Technologies, and Monsanto are among the major U.S. biotechnology companies, which number 1,500, with “combined annual revenue of about $70 Billion,” according to a Research and Markets report.
The report notes that biotech research demand “is driven by insurers' willingness to pay for new medical treatments.” It also notes, “Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery.”
In India, meanwhile, BioSpectrum Asia Edition reports on a paper from PricewaterhouseCoopers and Assn. of Biotechnology Led Enterprises focusing on that country's bio pharma strategy, noted that the market was growing 15% annually.
Assessing medium- and long-term challenges for India's biopharma industry, this report says “that if India was to become the world leading provider of affordable biopharmaceutical products by 2020, it cannot simply count on biosimilars and vaccines; it must also become a source of innovation.”
An analysis of the world's top 50 companies in pharmaceuticals/biopharmaceuticals is available from Bharat Book Bureau. The report examines the market pipeline from 2010 to 2015. Baratbook.com notes, “The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.”
-Jim Butschli
The report notes that biotech research demand “is driven by insurers' willingness to pay for new medical treatments.” It also notes, “Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery.”
In India, meanwhile, BioSpectrum Asia Edition reports on a paper from PricewaterhouseCoopers and Assn. of Biotechnology Led Enterprises focusing on that country's bio pharma strategy, noted that the market was growing 15% annually.
Assessing medium- and long-term challenges for India's biopharma industry, this report says “that if India was to become the world leading provider of affordable biopharmaceutical products by 2020, it cannot simply count on biosimilars and vaccines; it must also become a source of innovation.”
An analysis of the world's top 50 companies in pharmaceuticals/biopharmaceuticals is available from Bharat Book Bureau. The report examines the market pipeline from 2010 to 2015. Baratbook.com notes, “The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.”
-Jim Butschli
